PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade
Maisa Yoshimoto(University of Alberta), Andrew Evans(University of Dundee), Jeremy A. Squire(Universidade de São Paulo), Neil Fleshner(Princess Margaret Cancer Centre), Olga Ludkovski, Kyu Sang Song(Chungnam National University), Greg Trottier(Princess Margaret Cancer Centre), Joan Sweet(University Health Network), Anthony M. Joshua(St Vincent's Hospital Sydney), Keyue Ding(Ontario Institute for Cancer Research)
Cited by 80
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k